INTRODUCTION AND OBJECTIVES: OnabotulinumtoxinA (onabotA) 100U was shown to significantly reduce urinary incontinence (UI) and improve quality of life (QOL) at week (wk) 12 after treatment (tx) in overactive bladder (OAB) patients (pts) in 2 large, placebo (pbo)-controlled phase 3 trials. The earliest time for tx response was not assessed in the phase 3 trials. Here we present an interim analysis of an ongoing post-marketing study of onabotA tx response and QOL outcomes as early as wk 1 postinjection in OAB pts with UI.
INTRODUCTION AND OBJECTIVES: OnabotulinumtoxinA (onabotA) 100U was shown to significantly reduce urinary incontinence (UI) and improve quality of life (QOL) at week (wk) 12 after treatment (tx) in overactive bladder (OAB) patients (pts) in 2 large, placebo (pbo)-controlled phase 3 trials. The earliest time for tx response was not assessed in the phase 3 trials. Here we present an interim analysis of an ongoing post-marketing study of onabotA tx response and QOL outcomes as early as wk 1 postinjection in OAB pts with UI.
METHODS: OAB pts were randomized 1:1 to receive their 1st tx with onabotA 100U (n¼129) or pbo (n¼125). Pts could receive an additional tx with open-label onabotA 100U after fulfilling prespecified criteria. This interim analysis presents data up to wk 12 after tx 1. Assessments at wks 1, 2, 6 and 12 (primary timepoint) postinjection included the proportions of pts who achieved 100% UI reduction (ie, 00 dry 00 ; co-primary endpoint) and 75% and 50% UI reduction, mean change from baseline in daily episodes of urgency UI, micturition, nocturia, and in the Incontinence-QOL (I-QOL) total score. Adverse events (AEs) were also assessed.
RESULTS: Baseline mean UI episodes/day were 5.4 (onabotA) and 6.0 (pbo). As early as wk 1 after onabotA, significantly higher proportion of pts achieved 100% UI reduction vs pbo (24.0% vs 4.8%) and continued through wk 2 (25.6% vs 5.6%), wk 6 (32.6% vs 8.0%) and wk 12 (31.8% vs 7.2%) (P<.001 for all timepoints). Similarly, a significantly higher proportion of onabotA-treated vs pbo pts achieved 75% and 50% UI reduction as early as wk 1 (45.0% vs 20.8%, and 58.9% vs 36.0%, respectively; P<.001 for both) which continued through wk 12. Decreases were noted with onabotA vs pbo in other urinary symptoms as early as wk 1 and continued through wk 12. The early onset of onabotA response was also evidenced by the significantly greater improvements in I-QOL score at wk 1 (14.3 vs 5.6; P<.001) that were~1.5x the minimally important difference (MID; +10 points). At wks 2-12 after onabotA, improvements in I-QOL score were consistently~2-3x the MID and significantly greater than pbo (P<.001 for all timepoints). OnabotA was well tolerated; urinary tract infection was the most common AE (21.1% vs 6.4%).
CONCLUSIONS: This interim analysis showed a significant and consistent tx response with onabotA vs pbo in OAB pts as early as wk 1 postinjection, with significant reductions in UI episodes and improvements in OAB symptoms and QOL outcomes which continued through wk 12. OnabotA was well tolerated.
Source of Funding: Allergan plc.
PD26-11 SYMPTOMS AND NONINVASIVE PARAMETERS THAT PREDICT DETRUSOR UNDERACTIVITY IN MEN WITH LOWER URINARY TRACT SYMPTOMS: AN ANALYSIS USING A LARGE GROUP OF PATIENTS UNDERGOING PRESSURE FLOW STUDY
Ryo Namitome*, Mineo Takei, Ryosuke Takahashi, Tomoko Maki, Ken Lee, Shunichi Kajioka, Akito Yamaguchi, Masatoshi Eto, Fukuoka, Japan INTRODUCTION AND OBJECTIVES: Underactive bladder (UAB) is a symptom complex suggestive of detrusor underactivity (DU). However, DU can be diagnosed at present only on the basis of an invasive pressure flow study (PFS), which has hampered the development of clinical research and effective treatment for UAB.
Noninvasive diagnostic approaches for DU could potentially facilitate the diagnosis and research of this field. We therefore investigated to identify the noninvasive predictive factors for DU using a large group of patients undergoing PFS.
METHODS: We reviewed 2838 male patients who underwent PFS for lower urinary tract symptoms (LUTS). Age, International Prostate Symptom Score (IPSS), post-void residual volume (PVR), prostate volume (PV), and PFS parameters were obtained and analyzed. DU was defined as bladder contractility index <100. A multivariate logistic regression model was used to identify the factors associated with DU.
RESULTS: Of the patients, 1355 patients (46%) were classified as having DU. In univariate analysis, the prevalence of DU was significantly increased with increasing age (P<0.001) and PVR elevation (P<0.001), but decreased with increasing PV (P<0.001). The assessment of subjective symptoms using IPSS questionnaire revealed that patients with DU had a statistically significant higher occurrence of frequency (P¼0.01), intermittency (P¼0.001) and weak stream (P¼0.01) compared with non-DU patients. On the other hand, the occurrence of urgency symptom (P<0.001) was significantly lower in DU patients. In multivariate analysis, increasing age, PVR elevation, small PV, and several symptoms including frequency, intermittency, weak stream and urgency were selected as predictive factors for DU.
CONCLUSIONS: Several symptoms (frequency, intermittency, urgency and weak stream), increasing age, PVR elevation and small PV could be predictive factors of male DU. Combined evaluation of these factors might be useful for the diagnosis and better understanding of the clinical presentation of male DU.
Source of Funding: none

PD26-12 DOES STRESS INCONTINENCE DECREASE THE RATE OF CATHETERIZE AFTER INTRADETRUSOR ONABOTULINUMTOXINA IN THE MIXED INCONTINENCE PATIENT?
INTRODUCTION AND OBJECTIVES: Intradetrusor OnabotulinumtoxinA (ONA) is frequently used to treat urgency urinary incontinence. One possible side effect is incomplete bladder emptying requiring the temporary use of clean intermittent catheterization (CIC). The goal of this study is to examine if patient reported stress urinary incontinence (SUI) had an effect on the rate of CIC.
METHODS: A retrospective chart review of patients receiving ONA in the New York University Urology faculty practice between 5/ 2010 and 9/2016 were reviewed. Unique subjects were identified by CPT and/or J codes for intradetrusor injection of ONA. Charts were reviewed for demographic information, past medical and surgical history, symptoms of SUI (patients with SUI had urgency predominate mixed incontinence), post void residual (PVR) before and after first ONA infection and if catheterization was required after their first ONA injection. Subjects with a diagnosis of neurogenic bladder or a history Multiple Sclerosis, Parkinson's disease, Cerebral Vascular Accident with residual deficits, Spinal Cord injury, spinal surgery, urethral stricture, baseline catheterization requirement, or prior anti-incontinence surgery were excluded from the analysis. In general, CIC was recommended for patients with a PVR 200-349 ml with symptoms or for a PVR ¼ 350 ml with or without symptoms. The association between SUI and the need CIC after ONA was examined using a Fischer's Exact Test.
RESULTS: 265 charts were identified as having undergone intradetrusor ONA injection. A total of 115 subjects were are included in the analysis. Subject age at the time of injection ranged from 20-95 years with a mean age of 67.0 +/-17.2 years. Subjects with SUI had a mean age of 72.6 +/-10.1 years. 61.7% of subjects were female. Subjects with and without SUI had similar pre injection PVRs, 28.3 ml +/-47.2 ml and 37.7 ml +/-46.4 ml, respectively. The overall total rate of e510 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
